Eli Lilly & Co. (LLY), Medtronic, Inc. (MDT): Profiting from Diabetes Expenses

Wrap-Up

Both Eli Lilly and Medtronic, Inc. (NYSE:MDT) are in great positions to benefit from the growing obesity and healthcare trends. Eli Lilly & Co. (NYSE:LLY) has an advanced pipeline of diabetes treatment medications scheduled to make regulatory progress over the next few years. Empaglifozin, once approved, will put Eli Lilly & Co. (NYSE:LLY) in a market leading position for the treatment of the disease. Medtronic is in a great position to capture market share of new diabetes patients as the company offers the most technologically advanced disease management system on the market. Both companies are diversified across the entire healthcare industry and should benefit from rising health care globally. Lastly, I wanted to highlight the strong dividend yields of 3.7% from Eli Lilly and 2% from Medtronic, Inc. (NYSE:MDT).

The article Profiting from Diabetes Expenses originally appeared on Fool.com and is written by Nathaniel Matherson.

Nathaniel Matherson has no position in any stocks mentioned. The Motley Fool owns shares of Medtronic. Nathaniel is a member of The Motley Fool Blog Network — entries represent the personal opinion of the blogger and are not formally edited.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.